Company News: Page (1) of 1 - 04/21/17

Neurocrine Announces INGREZZA™ Long-Term Safety and Efficacy Data to be Presented at the 2017 American Academy of Neurology Annual Meeting

Additional results from largest ever clinical program in tardive dyskinesia to be highlighted as platform and poster presentations (April 21, 2017)

This article is no longer available,but here are some related topics.

Page: 1

Related Keywords:Pro AV,Presentors,Business,Business Issues,Presentation,People, Inc.,Disease,Therapy,Surgery,Medication,Science,Lifestyle,Medical,Business,Adults,Other,